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The metabolome is the set of small molecular mass organic compounds found in a 
given biological media. It includes all organic substances naturally occurring from the 
metabolism of the studied living organism, except biological polymers, but also xenobiotics 
and their biotransformation products. The metabolic fingerprints of biofluids obtained by 
mass spectrometry (MS) or nuclear magnetic resonance (NMR)-based methods contain a few 
hundreds to thousands of signals related to both genetic and environmental contributions. 
Metabolomics, which refers to the untargeted quantitative or semi-quantitative analysis of the 
metabolome, is a promising tool for biomarker discovery. Although proof-of-concept studies 
by metabolomics-based approaches in the field of toxicology and clinical chemistry have 
initially been performed using NMR, the use of liquid chromatography hyphenated to mass 
spectrometry (LC/MS) has increased over the recent years, providing complementary results 
to those obtained with other approaches. This paper reviews and comments the input of 
LC/MS in this field. We describe here the overall process of analysis, review some seminal 
papers in the field and discuss the perspectives of metabolomics for the biomonitoring of 
exposure and diagnosis of diseases.  
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Abbreviations 
MS: mass spectrometry; NMR: nuclear magnetic resonance; LC: liquid chromatography; 
MHz: MegaHertz; UPLC: Ultra performance liquid chromatography; HPLC: High 
performance liquid chromatography; TOF: time of flight; MS/MS: tandem mass 
spectrometry; API: atmospheric pressure ionisation; GSH: glutathione; NAPQI: N-acetyl-p-
quinone-imine; APAP: N-actetyl-p-aminophenol; GC: gas chromatography; MMC: Methyl 
mercury chloride; RC: respiratory chain; RCD: respiratory chain disease; Cr: creatine; PCr : 
phosphocreatine; CRC: Colorectal cancer; FT-ICR: Fourier Transform Ion Cyclotron 
Resonance; Q-Trap: Quadrupole linear trap; Q-TOF: Quadrupole Time-of-flight; CID : 
collision induced dissociation; DNA: Deoxyribonucleic acid; RNA: Ribonucleic acid; ESI: 
Electrospray ionization; QC: Quality control; PCA: Principal Components Analysis; PLS: 
Partial least squares or projection to latent structures; PLS-DA: Partial least squares 
discriminant analysis; OPLS: Orthogonal partial least squares; ALT: Alanine transaminase; 
AST: Aspartate transaminase; BUN: Blood urea nitrogen; ATP: Adenosine triphosphate; PC: 
Phosphatidylcholine; PSA: Prostate-Specific Antigen; TCA cycle: Tricarboxylic acid cycle; 
D-AAO: D-amino-acid oxidase; CYP: Cytochrome P450; PPARα: Peroxisome proliferator-
activated receptor alpha; ANIT: R-naphthyl isothiocyanate; CCl4: carbon tetrachloride; LDH: 






Introduction ........................................................................................................... 5 
What is a metabolite? ............................................................................................................. 5 
Metabolomics: a new approach for biomarker discovery ..................................................... 6 
How to measure metabolites? ................................................................................................ 9 
LC/MS based metabolomics: a practical approach ............................................. 10 
Design of the experiment ...................................................................................................... 11 
Sample preparation .............................................................................................................. 12 
Acquisition of metabolic fingerprints using LC/ESI-MS systems ......................................... 13 
Automatic detection of ions .................................................................................................. 14 
Statistical analyses ............................................................................................................... 15 
Identification ........................................................................................................................ 16 
Selected applications in the field of toxicology .................................................. 18 
LC/MS based metabolomics for toxicity biomarkers discovery. .......................................... 20 
LC/MS-based metabolomics for the building of predictive models of toxicity. ................... 22 
Toward mechanistic considerations ..................................................................................... 24 
Selected applications in the field of clinical chemistry ....................................... 25 




The metabolome is a set of small molecular mass organic compounds found in a given 
biological medium. Polymerized structures such as proteins and nucleic acids are excluded 
from the metabolome but small peptides such as the tripeptide glutathione are included. 
Molecules that constitute the metabolome are called metabolites.  
What is a metabolite? 
For some scientists, the concept of metabolite includes all the organic substances 
naturally occurring from the metabolism of a living organism and that do not directly come 
from gene expression. It should be stressed here that this definition could be applied as well to 
a microorganism, a human being or a plant. Two different kinds of metabolites can be 
distinguished based on their origin: endogenous and exogenous metabolites. 
Endogenous metabolites could be classified as primary and secondary metabolites. 
The firsts have a broad distribution in living species and are directly involved in essential life 
processes such as growth, development and reproduction. This is for example the case for 
amino-acids or glycolysis intermediates. At the opposite, secondary metabolites are species-
specific, have a restricted distribution and are synthesized for a particular biological function, 
as alkaloids for plants or hormones for mammals [1].  
Exogenous metabolites represent the biotransformation or metabolism products of 
exogenous compounds, resulting from phase I (modification of the original molecule to 
introduce a functional group) and/or phase II (conjugation) enzymatic conversion [2]. In this 
particular context, Holmes et al [3] proposed the concept of xenometabolome which is a 
description of the xenobiotic metabolite profile of an individual exposed to environmental 
pollutants, drugs, or exogenous molecules coming from food/dietary components such as 
phytochemicals [4]. This concept expands the approach developed in the early nineties in the 
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field of molecular epidemiology [5;6], thanks to the technical advances in analytical 
chemistry. 
In epidemiological studies, analyzing the xenometabolome could especially allow 
characterising environmental or occupational exposures to chemicals and contributes 
therefore to the determination of a metabolic phenotype. Crockford et al [7] demonstrated the 
potential of this approach by identifying metabolites of drugs such as acetaminophen or 
disopyramide by heterospectroscopy on data acquired with 600-MHz 1H NMR and UPLC-
TOF-MSE on urines obtained from more than 80 patients.  
Metabolomics: a new approach for biomarker discovery 
Biochemists have long been doing metabolomics, just like the Bourgeois 
Gentilhomme was speaking prose without knowing it (Molière – Bourgeois Gentilhomme II. 
4). It means that they suspected that patterns of biochemical substances could explain or 
describe inter-individual variation. Gates and Sweeley [8] mention that the concept of 
metabolic pattern was introduced by Williams [9;10] who used paper chromatography to 
compare the urines of 200,000 subjects including alcoholics, schizophrenics and residents of 
mental hospitals. He demonstrated that some characteristics of metabolic pattern could be 
associated with each of these groups. 
Griffiths and Wang [11] reported that metabolomics origins are found in the 60’s and 
70’s in the work of the Horning. Horning and Horning published several papers about 
metabolic profiles determination in urine by Gas Chromatography hyphenated among others 
to mass spectrometry [12;13]. At the same time, Robinson and Pauling performed a 
quantitative analysis of urine vapour and breath by gas chromatography [14].  
Metabolomics belongs to the “omics” techniques together with genomics, 
transcriptomics and proteomics that are related to the genome (DNA), the transcriptome 
(RNA), and proteome (proteins), respectively (Figure 1). The term metabolome (and 
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obviously metabolomics) was coined on the basis of genome and transcriptome. It appeared 
for the first time in a publication by Oliver in 1998 [15]. The metabolome reflects past events 
that include whole metabolism and the interaction with the environment, whereas the genome 
reflects the real and potential functional information of organism.  
Metabolomics/Metabonomics is the analysis of metabolome in a given condition. Both 
terms can be interchanged. Initially, metabolomics refers to  the measurement of the pool of 
cell metabolites [16] whereas metabonomics describes "the quantitative measurement of the 
dynamic multiparametric metabolic response of living systems to pathophysiological stimuli 
or genetic modification" [17;18]. Nicholson’s definition underlines the role of two major 
scientific disciplines used in metabonomics: analytical chemistry and biostatistics. By 
consistency, we use the term metabolomics in this manuscript. Metabolomics is therefore a 
data-driven approach, i.e. a technology based on the interpretation of information-rich data 
aimed at complementing the understanding of biological processes [19].  
Each individual (from every living species) owns his steady-state equilibrium called 
homeostasis. Interactions with the environment (exposure to drugs or chemicals) or the onset 
of a disease disrupts this homeostasis at different levels of the biological organization, 
including the metabolome. The concentrations of endogenous metabolites may be altered and 
xenometabolites may appear. Whereas the latter are obviously markers of exposure 
(biomarker of exposure for instance), specific signatures of disease or exposure (often referred 
to as metabolomic profile) could be found by the subtle analysis of endogenous metabolites. 
Biological markers or biomarkers are measurable internal indicators of molecular 
and/or cellular alterations that may appear in an organism after or during exposure to a 
toxicant and possible disease [20;21]. This definition is used in environmental and 
occupational toxicology and is larger than that of the National Institute of Health (NIH) that 
focuses on drug development and defines a biomarker as “a characteristic that is objectively 
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measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or 
pharmacological processes to a therapeutic intervention” [22]. 
Biomarkers could be divided into several categories that include biomarkers of 
exposure, biomarkers of effect and biomarker of susceptibility. Biomarkers are compounds or 
a set of compounds (metabolomic profile) that must be quantitatively, sensitively, 
specifically, and easily measurable on non-invasively collected biological media [23]. A 
biomarker of exposure is an indication of the occurrence and extent of exposure. It depends 
on the chemical fate of the exposed toxicant in the body. The biomonitoring of exposure has 
been used for a long time in occupational settings e.g. for the determination of lead [24] or 
benzene metabolites [25] in blood or urine.  
Biomarkers of (biochemical) effect(s) indicate that exposure has resulted in an 
interaction between the toxicant and a biological target. Mutagenic and carcinogenic 
substances that possess electrophilic function(s) bind to macromolecules such as proteins, 
DNA or lipids. Hemoglobin is often used in biomonitoring because of its long life span and 
ease of access. Oxidative stress perturbs the homeostasis of cell and leads to the production of 
specific substances such as 8-Hydroxy-2’-deoxyguanosine or to an imbalance of glutathione 
pathway [26].  
Biomarkers of susceptibility describe inter-individual differences in response to 
toxicants from genetic causes or from non genetics factors (age, liver disease, kidney disease, 
diet, dietary supplementation…). Polymorphisms of activating/detoxificating enzymes have 
been identified as key factors in the relationship between external (e.g. ambient air) and 
internal exposure (e.g. urinary excretion). Haufroid et al [27] demonstrated the relationship 
between the urinary excretion of phenylhydroxyethylmercapturic acids (a mercapturic acid 
metabolite of styrene) and the genetic polymorphism of glutathione S-transferase M1. A 
similar approach, referred to as pharmacometabolomics, has already been proposed to study 
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the response to drugs [28;29]. In this particular context, metabolomics acts as a functional 
genomics tool. 
How to measure metabolites? 
Because metabolites exhibit a high chemical diversity, ranging from sugars to lipids, it 
is impossible to perform their analysis in biological media with a single and universal 
technique. The two main analytical platforms which provide structural information relevant 
for metabolite identification rely on nuclear magnetic resonance (NMR) [30], or on mass 
spectrometry with different ion sources and mass analyzers [31-40]. Each of these tools 
provides complementary but sometimes redundant information, as emphasized by Lindon and 
Nicholson [41]. Beside NMR and Gas chromatography which were pioneering techniques for 
metabolomics, liquid chromatography hyphenated to mass spectrometry (LC/MS) has 
emerged as a popular and powerful tool, as shown in figure 2.  
Nuclear Magnetic Resonance (NMR) was one of the first method used for 
metabolomics [41-44]. It is a non destructive, rapid, and highly robust technique which 
produces highly informative structural information. However, NMR is less sensitive than 
mass spectrometry and requires, therefore, larger amounts of samples. NMR is often used 
without any prior separative method and does not require development as is the case with 
chromatography. However, as each metabolite participates to the NMR spectra, the 
deconvolution of signals is often a tedious process.  
The development of LC/MS significantly impacted biological research, including 
metabolomics. Initially, gas chromatography was the only separative method able to be 
hyphenated to mass spectrometry. However the use of gas chromatography is restricted to a 
small set of biological molecules, i.e., those that are volatile or could be derivatized. As a 
consequence, biological molecules of high molecular weight, such as proteins or nucleic 
acids, were excluded. The situation was improved by the introduction of atmospheric pressure 
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ionization mass spectrometry (API-MS)-based techniques combined with liquid 
chromatography which exhibit a good sensitivity, high dynamic range and versatility but also 
provide soft ionization conditions giving access to the molecular mass of intact biological 
molecules.  
One of the strengths of API-MS-derived tool is the high diversity of analyzers 
available: triple quadrupoles, ion traps, time of flight, Orbitrap and Fourier transform-ion 
cyclotron resonance instruments, the three latter providing high resolution and accurate mass 
measurements. Among these technologies, high resolution analyzers are becoming 
increasingly popular in the field of metabolomics because they provide (i) accurate mass 
measurement, which are useful for the determination of elemental composition of metabolites, 
and (ii) structural information with MS/MS or sequential MSn experiment, especially when 
ion products are analyzed at high resolution.  
The aim of this paper is to review the metabolomic approach for biomarker discovery 
in the field of toxicology and clinical chemistry, by focusing on the use of LC/MS. We will 
successively describe the overall process of analysis (i.e., data acquisition, statistical analyses 
and metabolites identification), review some seminal papers in the field and discuss the 
perspectives of metabolomics for biomonitoring of exposure and diagnosis of diseases.  
LC/MS based metabolomics: a practical approach 
A metabolomics experiment starts with an appropriate experimental design ensuring 
that the data will be relevant for further biological interpretation. The experimental step 
begins with the treatment of the biological samples before injection into LC/MS systems. The 
resulting metabolic fingerprints are then pre-processed using automatic peak detection 
softwares before being analyzed with appropriate statistical tools. Finally, identification of the 
discriminating signals is undertaken by combining mass spectrum analysis, database 
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consultation and other mathematics and informatics tools. All these critical steps are 
displayed in the Figure 3 and will be detailed in this section.  
 Design of the experiment 
One of the issues in metabolomics is the occurrence of confounding factors that mask 
the biological phenomenon to be investigated. These confounding factors can be of either 
analytical or biological origin and their impact has to be anticipated as far as possible by 
properly designing the experiment.  
Many putative confounding factors of biological origins have already been pointed out 
in published papers: age [45], gender [46], chronobiological effects [47;48], animal species 
and strains [49;50] and even environmental factors such as diet and gut microflora [51-53]. 
Some of these factors such as diet vary from one subject to another and cannot be easily 
controlled; the only possible option is to keep their presence in mind. Other factors such as 
age and gender should be balanced throughout the different groups to limit their impact on 
further statistical analyses. In this context, it is of special interest to investigate the metabolic 
profiles recorded from biofluids of “normal” healthy subjects in order to evaluate the impact 
of these physiological factors on the metabolite levels [54;55]. This should underpin the use 
of LC/MS based metabolomics in the clinical chemistry and toxicology arenas.  
Another important issue is the normalization of results. This is especially the case for 
urine samples. Indeed, contrary to most biological fluid or tissue samples, in which 
metabolites concentration is clearly related to volume or quantity drawn, urinary metabolites 
concentrations are very fluctuating because of urine volume and clearance variations. Thus, 
normalization of data is necessary to compare urinary metabolic profiles. It can be performed 
by weighting the signal abundances in each sample by the urinary volume, creatinine 
concentration, osmolality or total useful MS signal recorded from mass spectra [56], 
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according to the type of sample (spot urine or 24h collection) and information available 
(urinary creatinine concentration or volume, for example).  
Beside these biological confounding factors, analytical issues also have to be 
considered. This is for example the case with the clogging of the electrospray source which 
progressively alters the detection of analytes. This leads to a clear discrimination between 
samples analyzed at the beginning and at the end of an experiment which could hamper the 
visualization of the biological effect of interest. A way to address this issue is to randomize 
the samples throughout the sequence of injections.  
Sample preparation 
 Metabolite extraction strongly depends on the type of biological medium (i.e., cell 
extracts or biofluids), and also on the chemical structures of the metabolites to be preferably 
detected (i.e., polar compounds or lipids). Urines samples are often just diluted with water 
before injection into the LC/MS system [57-59], whereas other protein-rich biofluids such as 
plasma or cerebrospinal fluids are processed using organic solvents such as methanol, ethanol 
or acetonitrile [60;61]. The same kind of procedures may be applied to cell samples: after 
having been centrifuged to separate cells from supernatant, the cell pellet may be resuspended 
in water/cold organic solvent mixtures and then sonicated or mechanically agitated to disrupt 
cell membranes [62]. Tissues have first to be quickly collected and frozen by plunging them 
in liquid nitrogen for example. This is followed by homogenization in cold organic solvents 
such as methanol. A Folch derived extraction protocol can then be used either to clean the 
polar fraction from insoluble lipids or to analyze both polar and apolar fractions [63;64]. 
Then, depending on the type of organic solvent used for metabolite extraction, samples are 
diluted in the mobile phase or centrifuged, evaporated to dryness and finally resuspended in a 
solvent compatible with further injection into the LC/MS system.  
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Acquisition of metabolic fingerprints using LC/ESI-MS systems 
Initially, the acquisition of metabolic fingerprints was performed using LC coupled to 
electrospray mass spectrometers equipped with low resolution detectors such as triple 
quadrupole [65;66] or ion trap [67] analyzers. By these means, it was possible to separate and 
detect thousands of ions in biofluid samples. However, the interpretation of data was limited 
by both insufficient chromatographic separations and also identification issues. Indeed, it was 
difficult to link an experimental mass measured at low resolution and low accuracy to a 
metabolite among many others having the same nominal mass. These two issues have been 
partly addressed by the implementation of (i) ultra performance liquid chromatography 
(UPLC), which improved chromatographic resolution, peak capacity, and even sensitivity 
[39] and (ii) high-resolution mass spectrometers such as time-of-flight (TOF) and Fourier 
transform (FT) mass spectrometers.  
High- and ultra-high-resolution analyzers are becoming increasingly popular in the 
field of metabolite profiling because they provide accurate mass measurements which are 
useful for the discrimination between isobaric ions, and even isomers if their fragmentation 
patterns are different [68], leading to the detection of a higher number of signals than that 
obtained with low-resolution analyzers. Of course, accurate mass measurements also enable 
the determination of elemental compositions of metabolites for further identification.  
Finally, it is important to check for the consistency of analytical results before 
biological interpretation. Indeed ion abundances can decrease for long-term analysis (intra-
experiment variability), but also from an experiment to another (inter-experiments variability) 
because of the degradation of MS or chromatographic separation performances [69]. This 
complicates the automatic detection and alignment of features, and also stitching together of 
datasets. A  normalization step is thus required. To this end, a mixture of reference 
compounds can be injected at regular intervals to assess the performances of both the 
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chromatographic column (i.e.,consistency of retention times and peak widths of reference 
compounds) and the mass spectrometer during the experiments (i.e., consistency of mass 
accuracy and signal intensity of reference compounds). The same kind of approach can also 
be performed by using quality control (QC) samples that are representative of the biological 
samples to analyze [70], but this is not sufficient to normalize peak intensities. That is why 
many normalization approaches have been developed to overcome analytical variability, such 
as NOMIS (Normalization using Optimal selection of Multiple Internal Standards) or CCMN 
(Cross-Contribution Compensating Multiple Standard Normalization) [71], and also to 
facilitate comparison of datasets [72;73]. 
 Automatic detection of ions 
The aim is to represent the initial raw data in a matrix format which is compatible with 
subsequent statistical and biochemical analyses. As data formats are proprietary, a conversion 
step into universal data formats such as netCDF (Network Common Data Form - 
www.unidata.ucar.edu/software/netcdf/) [74] or mzXML [75] are required before running the 
data processing. A typical processing pipeline includes filtering, feature detection, alignment 
and normalization. This can be achieved by using dedicated commercial, or free and/or open-
access software, as already reviewed by Katajamaa et al. [76]. In the latter case, it is possible 
to have access to the algorithm and to modify or improve them. This is for example the case 
for XCMS [77;78] and MZmine [79].  
These software tools also differ by the implemented approaches. While the subtraction 
of the background noise often relies on filtering algorithms classically used in signal 
processing, large differences are observed at the level of the detection and alignment of the 
signals. As an example, the detection of peaks is achieved in both the retention time and m/z 
dimensions in an independent way with the software Mzmine (http: 
//mzmine.sourceforge.net/) [79], whereas the MatchedFilter algorithm of the XCMS software 
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detects the ions from m/z windows [77]. As an alternative of binning approaches, the 
centWave algorithm, which is also part of the XCMS software, performs a two-dimensional 
feature detection by using a combination of a density based technique to detect regions of 
interest in the m/z domain, and a Wavelet based approach to resolve chromatographic peaks 
[78]. At the opposite, other tools such as MathDamp (http:// mathdamp.iab.keio.ac.jp/) [80] 
make a comparative analysis from the original data without any signal detection step.  
Limited information about the validation of signal detection softwares is available in 
the literature. The main reasons are that most of the signals present in the metabolic 
fingerprints remain uncharacterized and the results of an automatic detection procedure of 
metabolites may be impacted by both the type of instrument and the biological medium. As a 
consequence, users have to evaluate the software with their own criteria in order to select that 
or the most suited one(s) regarding their instruments and the biological matrix.  
Tautenhahn et al. proposed an interesting approach to evaluate signal extraction 
software. It is based on the estimation of three parameters: the recall, which measures the 
fraction of relevant features that are extracted by the algorithm, the precision, which is the 
percentage of relevant items compared with the false positives, and the run time, which is the 
time required for the algorithm to achieve feature detection from a given data set [78]. 
Actually, many artefactual signals are present in the data matrices following automatic data 
extraction and signal alignment. They have been evaluated as around 400 for 100 relevant 
features [78]. One way to address this issue is to perform serial dilution of QC samples and 
select the features whose levels are correlated to the dilution factor [62;78].  
 Statistical analyses  
As for transcriptomics or proteomics, metabolomics relies on differential analyses of 
metabolic fingerprints which lead to a semi-quantitative expression of the results (i.e., 
decreased or increased area or intensity ratios). As it appears difficult to handle and to 
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compare data sets which contain several hundreds to thousands of signals, multivariate 
statistical analyses are required to address this issue [81] (Figure 4).  
Data exported from automatic peak detection software tools have first of all to be 
scaled. A typical procedure relies on unit variance scaling: the variables are centered and 
divided by their standard deviation. This gives an equal weight to signals exhibiting very 
different abundances. However, in some case, this may lead to a dilution of the analytical 
information of biological relevance and other methods such as pareto-scaling (the variables 
are centered and divided by the square root of their standard deviation) may be preferred.   
Once the data have been scaled, a preliminary step often relies on the use of 
unsupervised analyses such as principal component analysis. This descriptive method does 
not require any information about the nature of samples. It enables to visualize the 
organization of the original data in a two or three dimensional space by reducing the 
dimensionality of complex data sets. Explicative analyses are then performed by using 
supervised tools such as PLS (projection to latent structures or partial least squares) 
regression, PLS-discriminant analysis (PLS-DA), or more recently OPLS (Orthogonal 
Projection on Latent Structure) in order to facilitate the isolation of the ions responsible for 
the discrimination between groups [82].  
Finally, a clear distinction has to be done between exploratory studies that try to reveal 
new biomarkers whose biological relevance has to be established, and predictive studies that 
aim at classifying unknown subjects and for which the issues of statistical powerfulness and 
validation are critical [83]. 
 Identification  
The metabolite identification process using atmospheric pressure ionization mass 
spectrometry-based tools starts with the interpretation of the mass spectra in order to ensure 
that the signal of interest really corresponds to a monoisotopic ion and not to an isotope, 
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adduct or ion product generated during the ionization process. Several informatics and 
mathematics tools are available for that purpose. They are grouping the signals related to 
given metabolites according to (i) specific mass differences corresponding to isotopes, 
adducts, and product ions, and (ii) the correlations between the intensities of pairs of ions, 
either across several spectra within a sample or across all samples where the signals are 
observed [59;84;85] (Figure 5).  
One or few relevant elemental composition(s) is/are deduced from accurate mass 
measurements if high or very high resolution mass spectrometry is available, for further 
database queries. Collision induced dissociation (CID) spectra are then acquired and 
interpreted in order to get information about the chemical structure. At this stage, chemical 
database queries may be refined and the highlighted compounds, if any, are kept for further 
consideration or ruled out based on chromatographic retention time and CID mass spectra 
information. Complementary experiments (i.e., other sequential MSn experiments or H/D 
exchanges) may be required before obtaining or synthesizing the reference compounds. 
Finally, formal identification is achieved when the metabolite to be characterized exhibits the 
same retention time and CID spectra than those of the reference molecule.  
In the Metabolomics Standards Initiative [86], Sumner and al. have reported four 
different levels of identification according to the information provided :  
 (i) Identified compounds: a minimum of two independent and orthogonal types of data 
relative to an authentic compound analyzed under identical experimental conditions. In MS-
based techniques this could include: retention time/index and mass spectrum, or accurate 
mass and tandem MS.  
 (ii) Putatively annotated compounds: without chemical reference standards, based 
upon physicochemical properties and/or spectral similarity with public/commercial spectral 
libraries.  
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 (iii) Putatively characterized compound classes: based upon characteristic 
physicochemical properties of a chemical class of compounds, or by spectral similarity to 
known compounds of a chemical class.  
 (iv) Unknown compounds: although unidentified or unclassified these metabolites can 
still be differentiated based upon spectral data, thus enabling relative quantification.  
Mass spectrometry experiments alone may be sufficient when the metabolites to 
characterize are well described in databases, commercially available and discriminated from 
isomers thanks to an adequate chromatographic separation and/or characteristic MSn spectra. 
In this case, identification is achieved by matching the retention time and CID spectra of the 
compound of interest to those of the putatively related synthetic reference molecule. 
However, in many cases, the metabolites of interest are not reported in any biochemical or 
metabolomic databases and additional analytical tools such as NMR cannot be used due to a 
lack of sensitivity and/or insufficient chromatographic separation. The only solution is then to 
perform a careful and precise interpretation of CID spectra combined with additional 
experiments such as H/D exchange in order to provide new structural hypotheses that have to 
be assessed by further chemical synthesis [85].  
Selected applications in the field of toxicology 
Toxicology aims at studying adverse effects of chemicals (xenobiotics) on living 
organisms. The toxicity of a given compound refers to its ability to disrupt some biological 
functions at a certain level of biological organization (i.e., cell, tissue, or organ). It is related 
to the amplitude and the duration of the exposure and also to the degree of absorption of the 
substance by the organism, its distribution, biotransformation and elimination or 
accumulation. Understanding the mechanism of a toxic event is a challenging task, especially 
in the field of drug research and development. Indeed, target organ toxicity remains an issue 
and idiosyncratic toxicity, which refers to individual susceptibility in drug induced toxicity, is 
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often not detected before the drug has been on the market (Rofecoxib [87], Rimonabant [88]). 
Many in vitro, cell and animal models are designed to address these issues, but they may not 
be easily extrapolated to human. Biomarkers are useful to predict a toxic event before the 
occurrence of clinical events (biomarkers of early effect), to evaluate the severity of the 
poisoning (biomarkers of effect), and also to monitor exposed patients (biomarkers of 
exposure). This is another challenge because the occurrence of adverse effects has multiple 
origins including host environment interactions that are difficult to be caught using 
conventional approaches for biomarker discovery which are focused on limited biochemical 
and metabolic aspects.   
By achieving a global detection of molecular events at the different levels of 
biological organization, omics approaches may provide answers to these issues, as 
emphasized by early proof-of-concept studies in toxicogenomics [27], transcriptomics [89] 
and proteomics [90]. Metabolomics, which enables to track homeostatic disruptions and host-
environment interactions, is of particular interest in this context. Pioneering studies using 
NMR have already been published and also reviewed [17;19;44;91-96], and the consortium 
on metabonomic toxicology (COMET), coordinated by the Imperial College and including 
pharmaceutical companies, has started to develop expert models for the classification of 
toxicity based on 1H-NMR analysis [19]. However, none of them have ever been published 
until now. The development of LC/MS in this field is relatively recent. Several publications 
illustrating metabolomics applications in the field of toxicology are displayed in the table 1. 
They address biomarker discovery, predictive models and mechanistic considerations mainly 
in the field of hepato- and nephrotoxicity by using model toxicants. The input of LC/MS 
based approaches will be reviewed and discussed in this section.  
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 LC/MS based metabolomics for toxicity biomarkers discovery. 
Many studies are performed using different analytical platforms, such as 1H-NMR, 
GC/MS and LC/MS in order to maximize the metabolite detection coverage. Most studies 
attempt to address the issue of organ toxicity and aim at finding metabolite concentration 
changes related to the toxicant, occurring before clinical or histopathological detections and 
being more specific than conventional biomarkers such as alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) enzyme activities or bilirubin for hepatotoxicity, or 
blood urea nitrogen (BUN) for nephrotoxicity.  
Among these studies, acetaminophen (also known as N-acetyl-p-aminophenol, APAP) 
is frequently used as a model drug for hepatotoxicity. It is cleared from the body through 
hepatic glucuronide and sulphate conjugation. However, in case of overdose, these metabolic 
pathways are saturated and reactive metabolites such as N-acetyl-p-benzoquinone imine 
(NAPQI) are produced. NAPQI reacts with glutathione (GSH) to form a conjugate, which is 
subsequently degraded to a mercapturic acid derivative that can be detected in urine. 
However, NAPQI can also oxidize glutathione and in turn be reduced back to paracetamol 
[97]. When the GSH pool is depleted, NAPQI reacts with cell macromolecules. This 
mechanism is supposed to be one of the explanations for hepatic necrosis recorded in cases of 
APAP poisoning.   
Sun et al. (2008) investigated the acute and chronic toxicity of acetaminophen on male 
Sprague-Dawley rats by metabolomics using NMR and UPLC coupled to an electrospray Q-
TOF mass spectrometer [98]. Metabolic changes were matched up with histopathological 
observations and others markers of liver injury (serum ALT, AST and bilirubin) to highlight 
metabolites related to APAP induced toxicity. Necrosis was not observed in the course of the 
chronic study and was only detected at the highest dose (i.e., 1600 mg/kg) of the acute study 
at the 48 h time point. Urinary metabolite concentration changes were observed in both acute 
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and chronic studies from the 400 mg/kg dose. Both NMR and UPLC/MS pointed out 
depletions of antioxidants and energy metabolites. The decrease of 1-methylnicotinate levels 
observed by NMR was of particular interest because this molecule is linked to the glutathione 
biosynthesis pathway (this metabolite is produced during the conversion of S-
adenosylmethionine to S-adenosylhomocysteine). The decrease of urine 1-methylnicotinate 
concentration could be related to the depletion of S-adenosylmethionine observed by the 
authors using a targeted LC/MS/MS assay.  
These results have been confirmed by another study that focused on the regulation of 
the trans-sulfuration pathway in liver toxicity conditions using NMR, LC/MS, and also gene 
expression data: the expression of genes involved in the trans-sulfuration pathway was 
decreased in the liver, whereas taurine, creatine (observed by NMR) and S-
adenosylmethionine (observed with LC/MS) levels were increased in urine following APAP 
administration to rats [99].  
One of the strength of LC/MS-based metabolomics is the possibility to detect many 
xenobiotic related metabolites thanks to its high sensitivity. Sun et al. detected 6 APAP 
metabolites in rat urine and concluded that approximately 95 and 65 ions were related to 
APAP metabolites in negative and positive modes, respectively. They decided to remove 
these signals in order to facilitate the observation of endogenous metabolites whose levels 
were altered following APAP administration [98]. However, some of these so-called 
xenometabolites can also provide the toxicologist with mechanistic information about drug 
toxicity and thus being used as biomarkers. In a following study, Sun et al. [100] investigated 
the excretion kinetics of APAP metabolites in rat urine and observed that the concentrations 
of the APAP-N-acetylcysteine conjugate exhibited a significant correlation with AST activity, 
bilirubin, creatine and histopathological observations, and a significant anticorrelation with S-
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adenosylmethionine levels, suggesting that it is a good indicator of APAP-induced liver 
injury.  
 Although urine is the biofluid of choice for metabolomics (easily sampled, simple to 
analyze and providing investigators with information about polar metabolites including 
energy metabolites and xenometabolites) complementary information about lipids can be 
obtained from other biological media such as plasma. For example, using a LC/MS-based 
metabolomic approach, Chen et al. detected an accumulation of long chain acylcarnitines in 
plasma from APAP treated mice [101]. This was reinforced by the concomitant observation of 
increased free fatty acids and triglycerides plasma levels using colorimetric assays. Thanks to 
additional experiments performed on CYP 2E1 and PPARα null mice, the authors concluded 
that inhibition of fatty acid β-oxidation through the suppression of PPARα activation is a 
contributing mechanism of APAP-induced hepatotoxicity and that long chain acylcarnitines 
could be early biomarkers of APAP hepatotoxicity that may complement the measurements of 
GSH levels and serum AST or ALT activities.  
LC/MS-based metabolomics for the building of predictive models of toxicity.  
Beside biomarker discovery, other studies report the development of metabolomic-
based approaches for predicting and classifying different modes of toxicity. This is for 
example the case with La et al. in the field of chemical-induced hepatotoxicity [102]. They 
applied LC/MS to analyse urine samples of rats treated with four different hepatotoxins: R-
naphthyl isothiocyanate (ANIT), carbon tetrachloride (CCl4), APAP, and diclofenac. They 
found specific patterns of metabolites concentration changes that were characteristic of each 
hepatotoxin and managed to build a mathematical model exhibiting predictability higher than 
95% by using linear discriminant analysis and soft independent modelling of class analogy 
with residual distance. However, it is challenging to determine whether these patterns of 
metabolite concentrations are specific of a mode of organ toxicity (i.e., necrosis or 
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cholestasis), or rather of compounds or chemical families. To address this issue, several 
toxicants exhibiting different chemical structures, but the same mode of organ toxicity should 
have been included in the experimental protocol. Such an approach has been performed by 
Boudonk et al. in the field of nephrotoxicity.  
Boudonck et al. [103] reported on a metabolomic investigation on 3 drugs 
(gentamicin, cisplatin and tobramycin) inducing  proximal tubule nephrotoxicity. Urine and 
kidney were collected after one, five and twenty-eight dosing days and the samples were 
analyzed using GC and LC/MS. About 30% and 70% of the metabolites observed in kidney 
extracts were detected by GC/MS and LC/MS, respectively, whereas half of them were 
measured by both techniques in urine. Increases in amino-acids and polyamines were 
observed in urine and decreases in purine and pyrimidine nucleosides were detected in kidney 
tissues before observable kidney injury by conventional histology and clinical chemistry 
tools. Urinary metabolites exhibiting significant changes with all 3 drugs, such as branched 
chain amino-acids, hippurate and glucose at day 28 were then selected to build a predictive 
model based on classification trees in order to predict the onset of the nephrotoxicity at days 1 
and 5.  
Van Vliet et al. developed an in vitro model to evaluate neurotoxicity based on rat 
primary re-aggregating brain cell cultures followed by LC/MS-based metabolomics [104]. 
Cell cultures were exposed to the neurotoxic methyl mercury chloride (MMC) at 
concentrations ranging from 0.1 to 100µM or to the brain stimulant caffeine at concentrations 
ranging from 1 to100µM. The occurrence of cytotoxicity was assessed by the detection of an 
increased activity of the lactate dehydrogenase (LDH) in the culture media. No neurotoxicity 
was observed with caffeine, whereas it occurred from 1 µM with MMC. Interestingly, 
differences in metabolite concentrations were observed between control and MMC exposed 
sample, as emphasized by concentration dependent clusters observed on principal component 
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analysis score plots. The concentration of five metabolites was either increased (creatine, 
spermine) or decreased (glutamine, GABA and choline) in MMC samples, and these 
metabolites were found responsible for this clustering. To evaluate their model, van Vliet et 
al. tested 8 compounds exhibiting different modes of organ toxicity. On the PCA score plots, 
controls and hepato- and nephrotoxic compounds were part of the same cluster whereas 
neurotoxic compounds were clearly individualized.  
 Toward mechanistic considerations 
Williams et al (2005) showed the value of using MS-based metabonomics for 
elucidating the mechanism of toxicity of D-serine in rat. D-serine is a nephrotoxic amino acid 
that causes selective necrosis of renal proximal tubule cells in rats [105] by an unknown 
mechanism. Using 1H-NMR, Williams et al. [106] showed that D-serine-induced kidney 
tubular damage was associated with proteinuria, glucosuria and aminoaciduria, which have 
already been described as unspecific markers of tubular nephrotoxicity. Further LC/MS 
analyses led to the identification of several metabolites (hydroxypyruvate, glycerate, sebacic, 
xanthurenic and methyl succinic acids, acyl carnitine) that had not previously been detected 
by 1H NMR [107]. Interestingly, glycerate and hydroxypyruvate are produced from serine by 
the peroxisomal enzyme D-amino-acid oxidase (D-AAO). The authors hypothesized that 
hydroxypyruvate generates hydrogen peroxide, which induces a peroxisomal oxidative stress. 
The resulting peroxisomal dysfunction leads to decreased fatty acid metabolism and 
oxidation, as emphasized by the observation of decreased levels of the dicarboxylic acids such 
as sebacic and methylsuccinic acid, and acylcarnitins. Of note, a relationship between 
tryptophan catabolism and peroxisomal metabolism has already been reported [108] and is 
consistent with the perturbations observed in this study: increased excretion of tryptophan and 
decrease of xanthurenic acid and other TCA cycle intermediates. Finally, it has been shown in 
another study that the co-administration of D-serine and sodium benzoate, a potent 
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competitive inhibitor of renal D-amino-acid oxidase, prevents kidney injury, thus confirming 
the implication of this enzyme in the mechanism of toxicity [109].  
Finally, new insights into mechanisms of toxicity will probably be obtained through 
the coupling of classical histological and biochemical tools with other more recent omics and 
imaging approaches. In this context, a collaborative research effort in molecular system 
toxicology has been launched by the FDA's National Center for Toxicological Research and 
BG Medicine Inc. It is supported by 7 pharmaceutical companies and 3 technology providers 
and aims at investigating drug induced liver toxicity. Three days and twenty-eight days dosing 
studies are performed on related compound pairs, including a "clean" compound and a toxic 
one in order to highlight off-target molecular responses. Proteomics, LC/MS-based 
metabolomics and gene expression data are obtained from liver extracts, proteomics and 
LC/MS based metabolomics are obtained from plasma samples, and NMR based 
metabolomics experiments are performed on urine samples. These data are then confronted 
with histology and classical clinical chemistry tools. Preliminary findings are reported in a 
publication in which the performances of the analytical platforms on a first compound pair 
(entacapone and tolcapone) are presented and discussed [110]. 
Selected applications in the field of clinical chemistry 
 Clinical chemistry deals with any analysis performed on body fluids for medical 
purpose, including disease diagnosis and follow–up, and also therapeutic drug monitoring. 
MS-based approaches are used in clinical laboratories since the 1970s [111]. Most of them are 
targeted methods focusing on particular metabolites or chemical families. Currently existing 
tandem MS methods are used to carry out neonatal screening analysis using the same 
principles as metabolomics{American College of Medical Genetics/American Society of 
Human Genetics Test and Technology Transfer Committee Working Group, 2000 459 /id}. 
This is ultimately the tangible use of MS-derived discovery of novel biomarkers. Now, 
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technological and bioinformatical improvements of this last decade have enabled the 
implementation of MS-based global approaches, namely metabolomics, in the field of clinical 
chemistry. Table 2 displays some key applications of MS-based metabolomics to clinical 
chemistry. They address different medical areas such as cardiology, transplantation, human 
reproduction, diabetes, central nervous system diseases, or oncology.  
Thanks to the versatility of API-MS-based tools, MS-based metabolomics offers the 
possibility to provide chemists and physicians with various snapshots of different biological 
media such as plasma, urine, cerebrospinal fluids, cell extracts or tissue extracts obtained 
from biopsies, as shown in table 2. These snapshots may focus on concentration changes of 
selected metabolites sometime occurring at trace levels. Triple quadrupole mass spectrometers 
operated in the selected reaction monitoring mode are the instruments of choice for such 
targeted approaches thanks to their sensitivity. Snapshots may also focus on particular 
metabolite families such as carnitine species or lipids. In the first case, the selectivity of the 
detection may be brought by MS/MS detection, thanks to the constant neutral loss or parent 
ion scanning modes that are available on triple quadrupole instruments, whereas, in the 
second situation, it is rather obtained by specific sample treatment procedures, such as Folch 
extraction [112]. At last, the pictures may provide the user with an overview containing many 
features related to both genetic and environmental contributions (i.e., diet, lifestyle, gut 
microbial activity, drug intake, and exposure to pesticides, plasticizers or food 
preservatives…). The terminology of global approach has been coined for this kind of picture 
and high and ultra-high resolution mass spectrometers are the most frequently used 
instruments in this context. These aspects will be discussed in this section with selected 
applications.  
In targeted approaches, metabolites are selected with regards to their biological 
relevance to the field of investigation, or because they are representative for known metabolic 
 27
pathways. Metabolites exhibit very different structures and several analytical methods may be 
used in parallel for their detection. Sabatine et al. [113] and also Lewis et al. [114] used 3 LC 
columns for sugars and nucleotide, organic acids and amino-acid analyses, whereas Turer et 
al., used colorimetric methods to detect glucose, lactate, free fatty acids and pyruvate, and a 
MS-based method to profile amino-acids and carnitine derivatives [115]. Several tens to 
hundreds of metabolites may be detected using MS/MS analysis performed on triple 
quadrupole instruments in most cases. These metabolites are mainly amino-acids, sugars, 
organic acids involved in central and energetic metabolism, and also lipids (carnitine 
derivatives and phospholipids).    
Shaham et al. conducted a 3 steps study to highlight metabolic disorders linked to 
respiratory chain dysfunction [116]. They started to work on a cell model of chemical 
inhibition of the respiratory chain by applying LC-MS/MS using a triple quadrupole device 
and also 1H NMR. Among the 191 detected metabolites by LC-MS/MS, the levels of 32 of 
them were found to be altered by the RC inhibition. This was for example the case for 
alanine, lactate (both current biomarkers of RCD), glucose, creatine and others TCA-cycle 
intermediates. In the second step, they screened human plasma from two cohorts of patients 
with pathogenic mutation or abnormally low respiratory chain enzyme activity in muscle 
using the LC-MS/MS method. Concentration trends similar to those observed in culture 
media were found in the first cohort (16 patients and 25 controls) for 26 of the 32 metabolites 
previously pointed out. The levels of lactate (+107%), alanine (+46%), creatine (+233%) and 
uridine (-24%) were significantly different between patients and controls. To confirm the 
huge increase in creatine in plasma samples from patients suffering of a respiratory chain 
dysfunction, a second independent cohort (14 patients and 4 controls) was analyzed using 
another LC-MS/MS method. Increased concentrations of creatine (201%) were observed in 
patients whereas alanine and lactate levels did not significantly differ. This study suggests that 
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plasma creatine levels are more powerful biomarkers of respiratory chain dysfunction than 
alanine or lactate. Actually, creatine (Cr) is converted to phosphocreatine (PCr) by creatine 
kinase in the presence of ATP and the PCr/Cr balance reflects the cell energy state. In case of 
respiratory chain dysfunction, the low energy state makes that low intracellular ATP and PCr 
concentrations are observed, together with an accumulation of intracellular Cr which leads to 
an increased excretion of Cr in the extracellular medium.  
Oresic et al. reported on an ongoing cohort of children who progressed to type 1 
diabetes [117]. They analyzed serum metabolites before, around the time and after conversion 
using an UPLC/Q-TOF for lipid profiling and two dimensional gas chromatography coupled 
to a TOF mass spectrometer for polar metabolites. Although the mass detection was 
performed on a large mass range, these authors decided to keep only identified metabolites, 
i.e., 53 lipids and 75 metabolites, for further statistical analyses and biological interpretation. 
Results show that children who developed diabetes had metabolic perturbations before and 
during conversion such as increased levels of lysophosphatidylcholine, GABA, glutamic acid 
and leucine and decreased levels of succinic acid, PC, ketoleucine and glutamine. 
Normalization of profiles after the conversion indicates that those metabolic dysregulations 
precede B cell autoimmunity and disease onset. The interdependence of metabolic and 
immune system factors raises many questions, including the possible role of choline and 
intestinal microbiota in lipid dysregulation, or plasmalogen and oxidative damages toward B 
cells. However, tissue-specific mechanisms behind metabolic disturbances remain unclear: is 
the autoimmunity a physiological response aimed at restoring the metabolic homeostasis, or 
do metabolic dysregulations reflect an early stage of this immune response toward the B cell 
autoantigens that are not yet detectable?  
 Few papers using untargeted LC/MS based approaches in the field of clinical 
chemistry have been published. Two of them address the issue of cancer biomarker discovery. 
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Sreekumar et al. applied MS-based metabolomics in an attempt to identify biomarkers for 
non-invasive diagnosis and prognostic cancer invasion and disease aggressiveness [118]. To 
this end, they analyzed with two complementary GC and LC/MS methods the concentrations 
of several hundreds of metabolites across 262 prostate-related samples (42 tissues extracts, 
110 plasma and urine samples from biopsy-positive and negative prostate cancer patients). As 
amino acid metabolism and methylation of biomolecules were known to be involved in 
prostate cancer progression, they focused on metabolites of these pathways the levels of 
which were found increased in tissue samples from cancer patients. This was the case for 
sarcosine, a N-methyl derivative of glycine, which was significantly increased in tissues 
during disease progression from benign disease (undetectable) to metastatic stage (higher 
levels than in organ-confined disease). However, monitoring sarcosine levels in prostate 
tissues appears of limited interest because histology is already available and more powerful 
for the diagnosis and the prognosis of cancer. The authors then decided to turn to urine and 
found out that sarcosine was detectable but occurred at trace levels, with a modest but 
significant predictive value (more sensitive than PSA) for prostate-cancer diagnosis and 
disease progression. Beside the discussion about methylation and sarcosine, many other 
discriminating metabolites, identified or not were not taken into account. One reason for that 
is the lack of appropriate tools to visualize and synthesize omics data sets.  
Richie et al. [119] applied both targeted and non targeted metabolomics-based 
approaches in order to identify non invasive biomarkers of colorectal cancer (CRC). They 
started with a large-scale study on serum samples from several populations of different 
origins. Discriminating metabolites common to CRC patients whatever their ethnic or 
geographic origin were highlighted using a non targeted FT-ICR MS-based method combined 
with statistical analyses. A group of metabolites the levels of which were dramatically 
decreased in the 3 populations was pointed out, and thanks to the high resolution and accurate 
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mass measurement, the authors attributed a mass formula to each signal and noticed that these 
molecules belong to the same family. Then, they performed MS/MS experiments using a Q-
TOF instrument and identified the molecules of interest to be hydroxylated polyunsaturated 
ultra long-chain fatty acids. This was further confirmed by NMR experiments and MS/MS 
analysis of reference compounds. Finally a semi-quantitative method was developed on a 
triple quadrupole instrument operated in the selected reaction monitoring mode for biomarker 
validation purposes.  
Finally, although results from exploratory studies in the field of clinical medicine are 
promising, many of them should be cautiously interpreted. Indeed, many published studies 
involve reduced cohorts. This limits the power of statistical analyses and further isolation of 
discriminating ions. Furthermore, even thought such ions are underlined, their formal 
identification and the demonstration of their biological relevance will be required for further 
medical applications.  
Conclusion and perspectives 
The metabolome is characterized by a large diversity of chemical structures requiring 
diverse analytical platforms to reach its extensive coverage. NMR has been extensively used 
since the beginning of metabolomics, whereas the use of LC-MS has progressed and is now 
very popular because it is versatile, sensitive and brings complementary information about 
biomolecules such as peptides and lipids. The aim of this review was to introduce LC/MS-
based metabolomics and to present and discuss key applications focusing on toxicology and 
disease biomarkers. Whereas the published applications in the field of toxicology still remain 
proof-of-concept studies, due to the complexity and multifactorial origin of toxicity, the 
situation seems different in the field of clinical chemistry for which multiplexed targeted 
approaches provide the clinician with information on few tens to hundreds of metabolites by 
using MS/MS analysis performed on triple quadrupole mass spectrometers. Furthermore, 
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recent improvements in mass spectrometry have improved the efficacy of global approaches 
by facilitating the identification of metabolites of interest thanks to high resolution and 
accurate mass measurements.  
From a technical point of view, metabolomics is the combination of analytical 
chemistry, statistics and bioinformatics tools that are used separately or together to perform (i) 
sample preparation, (ii) acquisition of metabolic fingerprints, (iii) automatic detection of ions, 
(iv) statistical analyses and (v) identification. However, despite recent technological and 
conceptual improvements, metabolomics appears to be still in its infancy and each step that is 
mentioned above is a bottleneck in itself. How to accelerate metabolomics studies is therefore 
a titillating issue.  
Three major pitfalls must be highlighted: (i) analytical issues such as the difficulty to 
compare experiments one to another (developed in the “Acquisition of metabolic fingerprints 
using LC/ESI-MS systems”), (ii) the amount of information generated by metabolomics and 
(iii) the lack of chemical repositories designed for metabolomics studies (i.e., a central open 
source of mass and CID spectra acquired with various instruments in different laboratories) 
that will be helpful in the identification of discriminating signal. 
Metabolomic analysis processes generate, especially at the output of automatic ion 
detection, large matrix of data containing tens of thousands of variables (m/z–retention time). 
The reduction of data could be performed by taking advantage of signal redundancy, as 
previously explained. However, the main part of the information remains, until now, 
unexploited. The only alternative should be the systematic (and automatic) identification of 
all signals. This is actually one of the major rate-determining steps of metabolomics. The data 
sets obtained from high and ultra-high resolution mass spectrometry can be processed by 
informatics tool for automatic query in metabolic and metabolomic public databases with the 
measured accurate masses. Although such annotations are useful to start with biological data 
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interpretation, they have to be confirmed by a careful interpretation of the mass spectra, as 
shown in figure 6.  
The bottom of the figure 6 displays a peak list extract generated by an automatic 
detection software from a LC/MS based metabolomic analysis of human cell extracts. 
Putative annotations of signals are provided in the fourth column. They have been obtained by 
matching the experimentally measured masses with those of metabolites contained in public 
databases such as HMDB [120], KEGG [121] and Metlin [122]. They indicate the putative 
presence of spermidine, diaminopropane, 3-buten-1-amine, 1-Methylpyrrolinium and 
cyclopropylamine in cell extracts. Another annotation using a home-made spectral database 
confirmed the presence of spermidine, but shows that 3 of the other annotations are erratic 
because the related ions actually correspond to ion products of spermidine generated in the 
electrospray source during the desolvation process. This example highlights the complexity of 
API-MS-based data sets and a thorough inspection of mass spectra requiring spectral libraries 
is necessary before biological interpretation.   
Two different kinds of libraries are available for API-MS-based metabolomics: mass 
spectral and CID mass spectral libraries. The building of the first ones relies on careful 
interpretations of mass and CID spectra of reference compounds. They aim at annotating 
biological datasets, as shown in figure 6, whereas the latter are useful to confirm peak list 
annotations and to characterize unknown compounds. These libraries should be shared 
between users in order to make metabolite identification in various biofluids effective. 
Unfortunately, API-MS exhibits poor reproducibility and high inter-instrument variability in 
the generation of fragmentation patterns, thus hampering the constitution of universal 
databases as done with electron ionization mass spectrometry [123] or with NMR [124].  
  Despite these limitations, databases containing API mass spectra combined with CID 
spectra such as HMDB, Metlin, mass bank from metabolome.jp, and lipid maps are beginning 
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to be released. However, the use of such spectra for comparison and identification must be 
performed carefully and may lead to erroneous results [85]. This issue of spectral comparison 
begins to be addressed. For instance, Palit et al. proposed a fragmentation energy index for the 
normalization of collision energy [125] which is nevertheless restricted to ion trap 
instruments. Oberacher et al. designed a multicenter study in which 22 test compounds (drug 
standards) were sent to three different laboratories, where 418 tandem mass spectra were 
acquired using four different instruments from two manufacturers including Q-TOF, triple 
quadrupole, Q-Trap and FTICR mass spectrometers [126]. CID mass spectra were recorded 
without any standardization of experimental conditions and they were matched against a 
reference library using a sophisticated matching algorithm [127]. The high percentage of 
correct assignments suggests that it is possible to compare CID spectra obtained from 
different instruments and laboratories. The possibility of sharing CID spectral libraries and 
also MS data set repositories should improve the characterization of unknown metabolites of 
toxicological and clinical relevance.  
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Table1: MS-based metabolomics applications in toxicology 











Rat urine and plasma  Chan et Al. 2008 
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HPLC(HILIC) / IT-MS Mechanistic 
considerations 












Rat urine Previous study by 1H and 31P NMR 
(Williams et al. 2003) 





hepatotoxicity : role of 
PPARa 






Ochratoxin A induced 
nephrotoxicity 
Rat urine Additionnal GC/MS and 1H NMR 
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mercuric chloride induced 
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Liver Toxicity Biomarker Rat urine, plasma and 
liver 
Targeted: lipid, AA and polar LC-MS 
metabolomics 






Rat urine Additional 1H NMR experiments Schnackenberg et 





Detection of mercapturic 
acid metabolites of 
acetaminophen 












Cyclosporine A induced 
nephrotoxicity 




Ionizing radiation Human cells  Patterson et al. 
2008 [137] 
UPLC/TQ-MS Predictive model 
and biomarker 
discovery 
CCl4 and ANIT induced 
hepatotoxicity 
Rat serum Targeted on bile acids Yang et al. 2008 
[138] 
HPLC(C18)/IT-MS Predictive model Drug-induced 
nephrotoxicity 
Rat urine and kidney Additionnal GC/MS experiments Boudonck et al. 
2009 [103] 
direct introduction/TQ-MS Predictive model Methyl mercury chloride 
induced neurotoxicity 
Rat brain cell cultures  Van Vliet et 
al.2008 [104] 




Table 2: MS-based metabolomics applications in clinical chemistry 
Experimental conditions Topic Application Biological medium comment Reference 
UPLC(HILIC, C18)/IT-MS Cancer Kidney cancer Human urine Additional GC/MS experiments Kind at al. 2007 
[139] 
HPLC(HILIC)/IT-MS Cancer Kidney cancer Human urine  Kim et al. 2009 
[140] 
HPLC(C18)/IT-MS 
Cancer Woman's cancer (breast, 
ovarian, cervical) 
Human urine Targeted on hormones and 
nucleosides. Additional GC/MS 
experiments 
Woo et al. 2009 
[141] 
HPLC(C18)/IT-MS 
Cancer Breast cancer before and 
after tumor resection 
Human urine Targeted on nucleosides Cho et al. 2009 
[142] 
HPLC(C18)/IT-MS 
Cancer Breast cancer Human urine Targeted on nucleosides Cho et al. 2006 
[143] 
HPLC/IT-MS Cancer Breast cancer Human urine Targeted on nucleosides Frickenschmidt at 
al. 2008 [144] 
HPLC(C18)/TOF-MS Cancer Ovarian cancer Human serum  Guan et al. 2009 
[145] 
HPLC/IT-FT-MS Cancer Prostate cancer Human plasma, urine 
and tissue 
Additional GC/MS experiments Sreekumar et al. 
2009 [118] 
HPLC(C18)/QTOF-MS or 
TQ-MS, and Direct 
introduction/FTICR-MS 
Cancer Colorectal cancer Human serum Both targeted (Q-TOF TQ-MRM) and 
non targeted (FTICR) 
Ritchie et al. 2010 
[119] 
HPLC(C18)/QTOF-MS Cancer Bladder Cancer Human urine  Issaq et al. 2008 
[146] 
UPLC(C18)/TOF–MS Cancer Colorectal cancer Human urine  Ma et al. 2009 
[147] 
HPLC(C18)/TOF-MS Cancer Oral squamous cell 
carcinoma, oral lichen 
planus and oral leukoplakia 
Human saliva  Yan et al. 2008 
[148] 
Direct introduction or 
HPLC/QTRAP-MS 
Cancer Prostate cancer Human serum  Osl et al. 2008 
[149] 
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HPLC/TQ-MS Cardiology Myocardial ischemia Human plasma Targeted: Sugars and ribonucleotides 
(luna normal phase column), Organic 
acids (polar-RP column) and amino 
acids (Luna phenyl-hexyl column) 
Sabatine et al. 
2010 [113] 
HPLC/TQ-MS Cardiology Myocardial injury Human plasma Targeted: Sugars and ribonucleotides 
(luna normal phase column), Organic 
acids (polar-RP column) and amino 
acids (Luna phenyl-hexyl column) 
Lewis et al. 2008 
[114] 
Direct introduction/TQ-MS Cardiology Coronary Artery Disease or 
Left Ventricular 
Dysfunction 
Huma plasma Targeted Turer et al. 2009 
[115] 
HPLC(phenyl)/TQ-MS Cardiology Coronary artery disease  Human urine Targeted on amino acids Wang et al. 2009 
[150] 
UPLC(C18)/QTOF-MS Cardiology Silent myocardial ischemia Human plasma  Lin et al. 2009 
[151] 
UPLC(HILIC)/TQ-MS Endrocrinology Type 1 diabetes Rat urine Additionnal 1H NMR experiments Jankevics et al. 
2009 [57] 
UPLC(C18)/QTOF-MS Endrocrinology Type 1 diabetes Human plasma Targeted: lipidomics. Additionnal 
GC/MS experiments 












Roux-en-Y gastric bypass 
(RYGB) surgery 




Hepatic steatosis Mouse liver and blood Targeted: lipidomics Van Ginneken et 
al. 2007 [155] 
UPLC(C18)/QTOF-MS Hepato-
Gastroenterology 













Liver transplantation Human whole bile and 
extract 
Additionnal 1H NMR and HPLC-
NMR/MS experiments 




Intestinal transplantation Huma plasma  Li et al . 2008 
[159] 




Neurology Motor neuron disease Human plasma Additional GC/MS experiments Rozen et al. 2005 
[161] 
HPLC(Luna SCX)/IT-MS Reproduction Human embryo selection Human embryo 
culture medium 
 Marhuenda-Egea 
at al. 2009 [162] 
HPLC(C18)/IT-MS Reproduction Preterm birth biomarkers Human cervicovaginal 
fluid 
 Shah et al. 2008 
[163] 
UPLC(C18)/QTOF-MS Uigur chinese 
traditionnal 
medicine 




Dietary carbohydrate and 
metabolic syndrome 
Human plasma and 
tissue 
Targeted: lipidomics. Additionnal 
GC/MS experiments 
Lankinen et al. 
2009 [165] 
UPLC(C18)/QTOF-MS Rheumatology Ankylosing spondylitis  Human plasma Additional GC/MS experiments Gao et al. 2008 
[166] 
UPLC(C18)/QTOF-MS Nephrology Kidney injury in children 
after cardiac surgery 
Human urine 
 
Beger et al. 2007 
[167] 
HPLC(C18)/TOF-MS Inborn errors of 
metabolism 
Methylmalonic acidemia 




Wikoff et al. 2007 
[168] 
HPLC/QTRAP-MS Inborn errors of 
metabolism 
Respiratory chain diseases Human plasma Additionnal 1H NMR experiments. 
Targeted: Sugars and ribonucleotides 
(luna normal phase column), Organic 
acids (polar-RP or ion paring column) 
and amino acids (Luna phenyl-hexyl 
or HILIC column) 
Shaham et al. 
2010 [116] 
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Figure Legends 
Figure 1: Schematic representation of omics technologies. The flow of information starts 
from genes to metabolites running through transcripts and proteins.  
Figure 2: Number of publications dealing with metabolomics based on LC/MS in the fields of 
toxicology, clinical chemistry and others in the past 10 years (left axis) versus all 
metabolomics related publications (right axis). Search criteria in Pubmed were (metabolomics 
OR metabonomics) AND (liquid chromatography) AND (mass spectrometry) AND subject 
AND year[DP]” (subject are toxicology or disease, year ranges from 1999 to 2009). 
Figure 3: The MS-based metabolomics flow chart. 
Figure 4:  Multivariate statistical analyses 
Multivariate statistical analyses results are summarized into score and loading plots. The score 
plot represents the projection in two dimensions of samples onto principal components (PCs). 
The PCs constitute a new space which best carries the variation in the original data. The score 
plot shows how samples are dispersed in a 2- or 3-dimension space. Samples belonging to the 
same group are close from each other. The loading plot represents the projection of variables 
(m/z and retention time) onto PCs. Variables responsible for the discrimination between 
groups are far from the center of the loading plot, as emphasized with the two bar plots. 
Figure 5: How to address signal redundancy? 
This figure represents a Liquid Chromatography (LC) - Mass Spectrometry (MS) process and 
shows the origin of redundancy in MS signals. Four molecules represented by orange, green, 
yellow and blue dots are separated by LC. At retention time t=1, the “yellow molecule” is 
introduced into the ESI source. Into the source, pseudo molecular, adducts (e.g. with formic 
acid) and fragments (e.g. loss of functional group) ions are formed during the ionisation 
process (A). The resulting mass spectrum (B) reports the presence of those ions. The isotopic 
pattern of each ion (e.g. those of pseudo-molecular ion (C)) could be visualized when 
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enlarging the scale around the ion. Signals appearing at M+1, M+2 correspond to the 
isotopologues (13C, 15N…) of the ion. When fragments and adducts as well as isotopologue 
ions are taken account, it appears that many signals are actually related to the single yellow 
molecules. This phenomenon is called signal redundancy.  
Figure 6:  
Top of the figure: spermidine is analyzed by flow injection analysis–high resolution mass 
spectrometry (FIA-HRMS). The mass spectrum is exported as a list of signals (with 
composition and attribution) that constitutes a home-made spectral database after data 
interpretation.  
Bottom of the figure: Samples are analyzed by UPLC-MS and ions are extracted using 
automatic signal detection software. The m/z–retention time list is firstly annotated by search 
in Kegg, HMDB and Metlin databases and secondly by search in home-made spectral 
database.  
 
 
 
 
 
 
 
